Is Ozempic a Peptide? Semaglutide Explained

Is Ozempic a peptide? Yes: its active ingredient, semaglutide, is a synthetic 31-amino-acid peptide analogue of glucagon-like peptide-1 (GLP-1), a hormone naturally released from the gut after eating. This peptide structure determines how Ozempic works, how it must be stored, and why it is given as a weekly subcutaneous injection rather than a tablet. Understanding what it means for a medicine to be peptide-based helps patients make sense of its mechanism, its side effects, and the practical requirements around its use. This article explains the science in plain language, aligned with MHRA-authorised prescribing information and NHS guidance.

Is Ozempic a peptide and what does that actually mean?

Ozempic is a peptide medicine: semaglutide is a synthetic 31-amino-acid GLP-1 analogue that must be injected weekly because peptides are broken down by digestive enzymes if swallowed.

Yes, Ozempic is a peptide-based medicine: its active ingredient, semaglutide, is a synthetic peptide that mimics a naturally occurring hormone in the human body. A peptide is simply a chain of amino acids, the same building blocks that make up proteins. Semaglutide is a 31-amino-acid analogue of glucagon-like peptide-1 (GLP-1), a hormone released from the gut after eating.^[1][5] Because it is a peptide, semaglutide cannot be taken as a standard tablet and absorbed intact through the digestive system in the same way as many small-molecule drugs, which is why Ozempic is administered as a subcutaneous injection once weekly.

The term "peptide medicine" is increasingly used in clinical practice as this class of drug has grown. Semaglutide was developed by modifying the natural GLP-1 molecule to make it far more resistant to breakdown by the enzyme dipeptidyl peptidase-4 (DPP-4) and to increase albumin binding, extending its half-life to approximately one week.^[1][5] This structural engineering is what allows a single weekly injection to maintain stable blood levels throughout the dosing interval.

It is worth noting that Ozempic (semaglutide injection) and Wegovy (also semaglutide injection) are distinct licensed products. Ozempic is authorised by the MHRA for the treatment of type 2 diabetes in adults, while Wegovy is authorised for chronic weight management.^[1][9] Both share the same active peptide but are licensed for different indications and carry different dosing schedules, including Wegovy doses up to 7.2 mg weekly. Separate oral semaglutide products also exist (Rybelsus for type 2 diabetes, and Wegovy 25 mg tablets for weight management), each with their own licensed formulation and dosing; these are distinct from Ozempic and are not discussed further here.

How does semaglutide work in the body as a GLP-1 receptor agonist?

Semaglutide activates GLP-1 receptors in the pancreas, brain and stomach, stimulating glucose-dependent insulin release, suppressing glucagon, slowing gastric emptying and reducing appetite.

Semaglutide works by binding to and activating GLP-1 receptors found throughout the body, most importantly in the pancreas, brain, stomach and liver. GLP-1 receptors are part of the body's natural system for regulating blood glucose and appetite after a meal. When semaglutide binds to these receptors, it triggers several coordinated effects that together lower blood glucose and, at higher doses used in weight management, reduce appetite and food intake.

In the pancreas, GLP-1 receptor activation stimulates insulin secretion in a glucose-dependent manner, meaning insulin is only released when blood glucose is elevated.^[1][5] When semaglutide is used alone, this mechanism means the risk of hypoglycaemia (low blood sugar) is low. However, when semaglutide is used alongside insulin or a sulfonylurea, the risk of hypoglycaemia increases, and your prescriber may need to reduce the dose of those medicines when starting semaglutide.^[1][4] Simultaneously, semaglutide suppresses glucagon, a hormone that would otherwise signal the liver to release stored glucose into the bloodstream.

In the stomach, semaglutide slows gastric emptying, meaning food moves more slowly from the stomach into the small intestine. This contributes to a feeling of fullness after smaller meals and blunts post-meal glucose spikes. In the brain, particularly in appetite-regulating centres of the hypothalamus, GLP-1 receptor activation reduces hunger signals and increases satiety. These central effects are thought to be particularly important for the weight-loss outcomes observed with higher-dose semaglutide formulations.

Because semaglutide is a peptide analogue rather than a small molecule, it does not enter cells directly but acts exclusively at the cell surface receptor. This receptor-level specificity is central to both its therapeutic effects and its side-effect profile.

Why does it matter that Ozempic is a peptide-based medicine?

The peptide structure means Ozempic must be injected subcutaneously, stored refrigerated between 2°C and 8°C before first use, and never frozen or exposed to temperatures above 30°C.

The peptide nature of semaglutide has direct, practical consequences for how the medicine is stored, administered and handled. Because peptides are broken down by digestive enzymes in the gut, Ozempic cannot be swallowed as a conventional tablet and must be injected subcutaneously. The Ozempic pre-filled pen is designed for self-injection into the abdomen, thigh or upper arm, and patients are trained to rotate injection sites to reduce local skin reactions.

Storage requirements also follow from the peptide structure. Ozempic pens must be kept refrigerated between 2°C and 8°C before first use. After first use, the pen can be stored at room temperature below 30°C or in the refrigerator (2°C to 8°C) for up to 56 days, in line with the UK product information.^[1][2] Exposure to heat or freezing can denature the peptide and render the medicine ineffective, so patients should never freeze the pen or expose it to temperatures above 30°C.

The peptide origin also means that semaglutide is not a steroid, a stimulant or a synthetic small molecule of the kind associated with many older medicines. It is structurally related to a hormone the body already produces, which is part of why its mechanism of action is considered physiologically targeted. However, being peptide-based does not make a medicine free of side effects or risks, and the MHRA-authorised prescribing information should always be followed.

Semaglutide is not recommended during pregnancy. Women of childbearing potential are advised to use contraception while taking semaglutide and for a period after stopping, as the medicine may remain in the body for some weeks.^[1][11] Semaglutide is also not recommended during breastfeeding. Anyone who is pregnant, planning a pregnancy or breastfeeding should discuss this with their prescriber before starting or continuing treatment.

What side effects should you watch for with this type of medicine?

The most common side effects are gastrointestinal; serious risks include acute pancreatitis, gallbladder problems, hypoglycaemia (with insulin or sulfonylureas) and anaphylaxis, all requiring prompt medical attention.

The most commonly reported side effects of semaglutide, as a GLP-1 receptor agonist peptide, are gastrointestinal in nature and include nausea, vomiting, diarrhoea, constipation and abdominal discomfort. These effects are largely a consequence of the medicine slowing gastric emptying and acting on gut GLP-1 receptors. They are most pronounced when starting treatment or after a dose increase, and they typically improve over several weeks as the body adjusts. Eating smaller, lower-fat meals and avoiding rich or spicy foods can help manage these symptoms during the early weeks. It is important to stay well hydrated, particularly if you experience vomiting or diarrhoea. If you are unable to keep fluids down, or if you have pre-existing kidney problems, seek medical advice promptly, as dehydration can affect kidney function.

More serious but less common effects that require prompt medical attention include:

• Acute pancreatitis: The UK SmPC notes that acute pancreatitis has been reported with semaglutide, including post-marketing reports of necrotising pancreatitis and reports with a fatal outcome.^[1][10] If you develop persistent, severe abdominal pain, particularly if it radiates to the back, stop taking semaglutide and seek urgent medical assessment. Contact your GP or, if symptoms are severe and sudden, attend A&E.

• Gallbladder problems: Cholelithiasis (gallstones) and cholecystitis have been reported.^[1][17] Symptoms include upper right abdominal pain, fever and jaundice.

• Hypoglycaemia: When semaglutide is used in combination with insulin or a sulfonylurea, the risk of low blood sugar is increased.^[1][4] Symptoms include shakiness, sweating, confusion and palpitations. Your prescriber may reduce the dose of your insulin or sulfonylurea when you start semaglutide.

• Diabetic retinopathy: In people with pre-existing diabetic eye disease, particularly pre-proliferative or proliferative retinopathy, rapid improvement in blood glucose control may be associated with transient worsening.^[1][15] Regular eye screening is important for anyone with known diabetic eye disease.

• Hypersensitivity reactions: Serious allergic reactions, including anaphylaxis and angioedema, have been reported. If you develop swelling of the face, lips or throat, or difficulty breathing, call 999 immediately.

Suspected side effects can be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk. If you are unsure whether a symptom is related to your medicine, contact your GP or call NHS 111 for advice.

Who can get Ozempic on the NHS and what are the alternatives?

Ozempic is available on the NHS for adults with type 2 diabetes meeting NICE criteria; alternatives include tirzepatide (Mounjaro) and, for weight management, Wegovy or liraglutide (Saxenda).

Ozempic is available on the NHS for adults with type 2 diabetes, subject to NICE guidance and local implementation by Integrated Care Boards (ICBs). NICE recommends semaglutide (Ozempic) as an option within specific treatment pathways for type 2 diabetes, typically when blood glucose is not adequately controlled with other medicines and certain clinical criteria are met.^[3][4] In England, NICE Technology Appraisals carry a mandatory funding requirement, meaning ICBs are required to fund treatments within set timelines once a positive appraisal is issued; however, local pathways, capacity and referral processes influence how and when patients access treatment in practice. Eligibility is assessed by a GP or diabetes specialist.

For weight management, Ozempic is not licensed for that purpose in the UK. Wegovy (semaglutide injection at higher doses, up to 7.2 mg weekly) holds a separate MHRA authorisation for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity. Wegovy is available through specialist NHS weight management services in England, subject to NICE technology appraisal criteria and ICB commissioning arrangements.

Alternatives within the same or related drug classes include:

• Liraglutide (Saxenda): Licensed for weight management, administered daily by injection.

• Tirzepatide (Mounjaro): A dual GIP and GLP-1 receptor agonist, MHRA-authorised for both type 2 diabetes and chronic weight management in the UK.^[6][12]

• Orforglipron (Foundayo): A newly licensed GLP-1 receptor agonist for weight management; patients should discuss suitability with their prescriber.^[14]

For those considering private access to weight-management consultations, Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online consultations, with prescriber review and pharmacist support, where a medicine such as Mounjaro may be one option a prescriber considers if it is clinically appropriate. Anyone seeking treatment should ensure their provider is registered with the GPhC (for pharmacies in Great Britain) or the PSNI (for pharmacies in Northern Ireland), and that prescribers are registered with the GMC at gmc-uk.org.

Scientific References

1. Ozempic 0.25 mg solution for injection in pre-filled pen – Summary of Product Characteristics.
2. Ozempic 0.5 mg solution for injection in pre-filled pen – Summary of Product Characteristics.
3. Summary of NICE guidance for GLP-1 receptor agonists and tirzepatide in adults.
4. Further medication | Type 2 diabetes in adults: management (NG28).
5. Semaglutide | Drugs – BNF – NICE.
6. Tirzepatide | Drugs – BNF – NICE.
7. Semaglutide for managing overweight and obesity (TA875).
8. Medicines regulator approves up to 7.2 mg dose of semaglutide (Wegovy) for patients with obesity only.
9. MHRA approves GLP-1 receptor agonist semaglutide to reduce risk of serious heart problems in obese or overweight adults.
10. GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists: strengthened warnings on acute pancreatitis including necrotising and fatal cases.
11. Women on “skinny jabs” must use effective contraception, MHRA urges in latest guidance.
12. MHRA authorises diabetes drug Mounjaro (tirzepatide) for weight management and weight loss.
13. Tirzepatide – NHS medicines information.
14. UK first in Europe to authorise orforglipron (Foundayo) for weight management and type 2 diabetes.
15. NG242 Diabetic retinopathy: management and monitoring – effectiveness of intensive treatments to lower blood glucose levels.
16. Husain M et al. Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy. Diabetes Obes Metab. 2018..
17. He L et al. Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases. JAMA Intern Med. 2022..
18. Alkhezi OS et al. Gastrointestinal safety of semaglutide and tirzepatide vs. placebo in obese individuals without diabetes: a systematic review and meta-analysis. Ann Saudi Med. 2025..
19. Lincoff AM et al. Safety profile of semaglutide versus placebo in the SELECT study. Obesity (Silver Spring). 2025..
20. Smits MM, Van Raalte DH. Safety of Semaglutide. Front Endocrinol. 2021..
21. Andersen A et al. Impact of chemical structure, lipidation and formulation on luminal stability and intestinal absorption of GLP-1 analogues. J Control Release. 2025..
22. Ozempic | European Medicines Agency (EMA).

Frequently Asked Questions